Aromatase inhibitors may increase the risk for coronary heart disease in women with early breast cancer

Accumulating evidence shows that aromatase inhibitors may increase the risk for coronary heart disease in women with early breast cancer. Only large and well-designed population-based outcome studies could give a definitive answer to this concern. Based on current evidence and knowledge clinicians should take possible cardiac toxic effects of aromatase inhibitors into consideration when perscribing these agents

 

 

 

 

Bibliographic Reference:

Seruga B et al.: "Association of aromatase inhibitors with coronary heart disease in women with early breast cancer", Cancer Invest. 2014 Apr;32(4):99-104

 

 

 

 

 

Bostjan Seruga

Sector of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia